clentiazem

03/15/1993 - "The results of this short-term study suggest that clentiazem given twice daily in doses of 80 or 120 mg/day is safe and effective monotherapy in the treatment of stable angina."
03/15/1993 - "To date, this is the first large efficacy and safety study of clentiazem in patients with stable angina. "
03/15/1993 - "The efficacy and safety of clentiazem were assessed in 199 patients with stable angina in a dose-ranging, placebo-controlled, double-blind, parallel design study. "
03/15/1993 - "A dose-response study of clentiazem, a chloro-derivative of diltiazem, in patients with stable angina. "
10/01/1992 - "Clentiazem, 8-chloro diltiazem, is a calcium channel blocker currently undergoing evaluation for the treatment of stable angina and hypertension. "

10/01/1992 - "As patients with ischaemic disorders often present some degree of heart failure, the aim of this study was to investigate the effect of congestive heart failure on clentiazem (200 micrograms kg-1, i.v. bolus) pharmacokinetics in a canine model. "
03/01/1997 - "Therefore, our objective was to assess coronary and cardiac sensitivity to clentiazem in an experimental model of chronic heart failure (cardiomyopathic hamster, UM-X7.1, > 200 day old). "
10/01/1992 - "It is concluded that, in our model, congestive heart failure significantly modifies clentiazem disposition. "
10/01/1992 - "Effect of congestive heart failure on clentiazem pharmacokinetics in a dog model."
03/01/1997 - "Although the mechanisms involved in the vascular desensitization to clentiazem are still unknown, our findings may provide an additional explanation for the variable efficacy of calcium antagonists in the treatment of heart failure."

03/01/1991 - "If hearts were subjected to a 30-minute period of no-flow ischemia, the addition of 0.5 microM TA-3090 to the perfusate before ischemia significantly improved reperfusion recovery of mechanical function. "
03/01/1991 - "The protective effects of TA-3090 were not observed if TA-3090 was added at the time of reperfusion and were not related to a depression of function before ischemia. "
08/01/1998 - "These results indicate that reduction of Ca2+ entry from the extracellular space to the myocyte, as reflected by negative inotropism during pretreatment, is required for clentiazem to protect myocardium in a model of global ischemia and reperfusion."
08/01/1998 - "In the clentiazem group, [Ca2+]i showed no significant changes during ischemia or reperfusion. "
02/01/1994 - "Pretreatment with clentiazem lessened the decrease in cerebral blood flow (control, 4.8 +/- 1.4%; clentiazem, 14.1 +/- 4.1% of the preischemic level; P < .05) and prevented the disappearance of electroencephalographic activity in some rats during ischemia. "

07/01/1990 - "It is concluded that TA 3090 is a safe and effective treatment for mild to moderate hypertension."
04/01/1988 - "Development of hypertension in young SHR was significantly suppressed by chronic treatment with TA-3090 at a daily dose of 10 mg/kg p.o. "
10/05/1988 - "After intravenous injection, both diltiazem and TA-3090 significantly reduced vascular resistances of the major target organs of hypertension: heart, brain and kidneys in SHR. "
04/01/1988 - "The hypotensive effect of a new 1,5-benzothiazepine derivative, TA-3090 ((+) (2S,3S)-3-acetoxy-8-chloro-5-(2-(dimethylamino)ethyl)-2, 3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4-(5H)-one maleate), was studied in various models of experimental hypertension. "
10/01/1992 - "Clentiazem, 8-chloro diltiazem, is a calcium channel blocker currently undergoing evaluation for the treatment of stable angina and hypertension. "

04/01/1995 - "Clentiazem (1, 3, and 10 mg/kg/day) administered orally for 23 days after the development of stroke increased the avoidance rate in a dose-dependent manner. "
01/01/1994 - "These results suggest that clentiazem treatment in the acute and subacute phases of stroke is beneficial."
01/01/1994 - "Effect of clentiazem (TA-3090) with posttreatment on neurologic and histologic disorders of stroke-prone spontaneously hypertensive rats with history of stroke."
06/01/1992 - "The hypotensive effect and organ-protective action by clentiazem may be involved in its prophylactic action against stroke."
06/01/1992 - "Chronic treatment with clentiazem (300 or 1000 ppm) delayed the occurrence of stroke and death in a dose-related manner without any hypotensive action when measured by the tail-cuff method. "